TY - JOUR
T1 - Colesterolo e rischio cardiovascolare
T2 - Percorso diagnostico-terapeutico in Italia
AU - Gulizia, Michele Massimo
AU - Colivicchi, Furio
AU - Ricciardi, Gualtiero
AU - Giampaoli, Simona
AU - Maggioni, Aldo Pietro
AU - Averna, Maurizio
AU - Graziani, Maria Stella
AU - Ceriotti, Ferruccio
AU - Mugelli, Alessandro
AU - Rossi, Francesco
AU - Medea, Gerardo
AU - Parretti, Damiano
AU - Abrignani, Maurizio Giuseppe
AU - Arca, Marcello
AU - Filardi, Pasquale Perrone
AU - Perticone, Francesco
AU - Catapano, Alberico
AU - Griffo, Raffaele
AU - Nardi, Federico
AU - Riccio, Carmine
AU - Di Lenarda, Andrea
AU - Scherillo, Marino
AU - Musacchio, Nicoletta
AU - Panno, Antonio Vittorio
AU - Zito, Giovanni Battista
AU - Campanini, Mauro
AU - Bolognese, Leonardo
AU - Faggiano, Pompilio Massimo
AU - Musumeci, Giuseppe
AU - Pusineri, Enrico
AU - Ciaccio, Marcello
AU - Bonora, Enzo
AU - Forti, Giorgio Cantelli
AU - Ruggieri, Maria Pia
AU - Cricelli, Claudio
AU - Romeo, Francesco
AU - Ferrari, Roberto
AU - Maseri, Attilio
PY - 2016
Y1 - 2016
N2 - Atherosclerotic cardiovascular disease still represents the leading cause of death in western countries. A wealth of scientific evidence demonstrates that increased blood cholesterol levels have a major impact on the outbreak and progression of atherosclerotic plaques. Moreover, several cholesterol-lowering pharmacological agents, including statins and ezetimibe, have proven effective in improving clinical outcomes. This document is focused on the clinical management of hypercholesterolemia and has been conceived by 16 Italian medical associations with the support of the Italian National Institute of Health. The authors have considered with particular attention the role of hypercholesterolemia in the genesis of atherosclerotic cardiovascular disease. Besides, the implications of high cholesterol levels in the definition of the individual cardiovascular risk profile have been carefully analyzed, while all available therapeutic options for blood cholesterol reduction and cardiovascular risk mitigation have been considered. Finally, this document outlines the diagnostic and therapeutic pathways for the clinical management of patients with hypercholesterolemia.
AB - Atherosclerotic cardiovascular disease still represents the leading cause of death in western countries. A wealth of scientific evidence demonstrates that increased blood cholesterol levels have a major impact on the outbreak and progression of atherosclerotic plaques. Moreover, several cholesterol-lowering pharmacological agents, including statins and ezetimibe, have proven effective in improving clinical outcomes. This document is focused on the clinical management of hypercholesterolemia and has been conceived by 16 Italian medical associations with the support of the Italian National Institute of Health. The authors have considered with particular attention the role of hypercholesterolemia in the genesis of atherosclerotic cardiovascular disease. Besides, the implications of high cholesterol levels in the definition of the individual cardiovascular risk profile have been carefully analyzed, while all available therapeutic options for blood cholesterol reduction and cardiovascular risk mitigation have been considered. Finally, this document outlines the diagnostic and therapeutic pathways for the clinical management of patients with hypercholesterolemia.
KW - Atherosclerosis
KW - Diagnostic and therapeutic pathways
KW - Hypercholesterolemia
KW - PCSK9 inhibitors
KW - Statins
KW - Sustainable healthcare
UR - http://www.scopus.com/inward/record.url?scp=84978835838&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84978835838&partnerID=8YFLogxK
M3 - Articolo
AN - SCOPUS:84978835838
VL - 17
SP - 3S-57S
JO - Giornale Italiano di Cardiologia
JF - Giornale Italiano di Cardiologia
SN - 1827-6806
IS - 6
ER -